The combination of pexidartinib (KIT, CSF1R, and FLT3 inhibitor) and sirolimus, an mTOR inhibitor (NCT02584647), demonstrated efficacy in 12 out of 18 patients with advanced sarcoma, including five with MPNST. This evidence concerns the gene MTOR and malignant peripheral nerve sheath tumor.